Flamethrowers: Blood cells and cancer thrombosis risk

Hematology (United States)

Volumn 2014, Issue 1, 2014, Pages 410-417

  Pabinger, Ingrid ^a   Posch, Florian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BLOOD; BLOOD CELL; COMPLICATION; DISEASE MODEL; HUMAN; MEMBRANE MICROPARTICLE; METABOLISM; NEOPLASM; PATHOLOGY; RISK FACTOR; THROMBOSIS;

ANIMALS; BLOOD CELLS; CELL-DERIVED MICROPARTICLES; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; RISK FACTORS; THROMBOSIS;

EID: 84937543186     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2014.1.410     Document Type: Article

References (45)

1. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res. 2013;131(Suppl 1):S59-S62.
2. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-2829.
3. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609.
4. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382.
5. Thomson SP, Kessler JF, Miller TP. Leukocyte concentrations in discrimination of benign from malignant lung lesions. Am J Med. 1986;80(6):1035-1040.
6. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703-2708.
7. Konigsbrugge O, Lotsch F, Reitter EM, et al. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. J Thromb Haemost. 2013;11(11):1993-2000.
8. Blix K, Jensvoll H, Braekkan SK, Hansen JB. White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism-the Tromso study. PLoS One. 2013;8(9): e73447.
9. Thaler J, Ay C, Kaider A, et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol. 2014 [Epub ahead of print] doi: 10.1093/neuonc/nou106
10. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880-15885.
11. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411-2416.
12. Maestu I, Pastor M, Gomez-Codina J, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol. 1997;8(6):547-553.
13. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32): 13076-13081.
14. Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2014;40(3): 277-283.
15. Martinod K, Demers M, Fuchs TA, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A. 2013;110(21):8674-8679.
16. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost. 2011;9(9): 1795-1803.
17. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011; 29(15):2099-2103.
18. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 ± 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124-4129.
19. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16(8):887-896.
20. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lammle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012;120(6):1157-1164.
21. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. 2011;9(11):2313-2321.
22. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13(2):85-94.
23. Halvorsen H, Olsen JO, Osterud B. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. J Leukoc Biol. 1993;54(4):275-282.
24. Lwaleed BA, Francis JL, Chisholm M. Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression. BJU Int. 1999;83(4):476-482.
25. Lwaleed BA, Chisholm M, Francis JL. The significance of measuring monocyte tissue factor activity in patients with breast and colorectal cancer. Br J Cancer. 1999;80(1-2):279-285.
26. Adany R, Kappelmayer J, Berenyi E, Szegedi A, Fabian E, Muszbek L. Factors of the extrinsic pathway of blood coagulation in tumour associated macrophages. Thromb Haemost. 1989;62(3):850-855.
27. Lindholm PF, Lu Y, Adley BP, et al. Role of monocyte-lineage cells in prostate cancer cell invasion and tissue factor expression. Prostate. 2010;70(15):1672-1682.
28. Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012;119(23):5543-5552.
29. Mandala M, Barni S, Prins M, et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol. 2010;21(4):871-876.
30. Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hamostaseologie. 2014;34(1):54-62.
31. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8(1):114-120.
32. Riedl J, Kaider A, Reitter EM, et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost. 2014;111(4):670-678.
33. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986-993.
34. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood. 2008;111(10):4902-4907.
35. Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients. Hamostaseologie. 2012;32(2):127-131.
36. Thaler J, Ay C, Weinstabl H, et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol. 2011;90(4):447-453.
37. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6(9):1517-1524.
38. Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012;119(23):5543-5552.
39. Thaler J, Koder S, Kornek G, Pabinger I, Ay C. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res. 2014;163(2):145-150.
40. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res. 2010;125(6):511-512.
41. Auwerda JJ, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011;105(1):14-20.
42. Hernández C, Orbe J, Roncal C, et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost. 2013;110(3):598-608.
43. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830-6840.
44. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012;10(7): 1363-1370.
45. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008;6(11):1983-1985.